U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C18H24I3N3O8
Molecular Weight 791.1126
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of IOXILAN

SMILES

CC(=O)N(CC(CO)O)c1c(c(c(c(c1I)C(=NCC(CO)O)O)I)C(=NCCO)O)I

InChI

InChIKey=UUMLTINZBQPNGF-UHFFFAOYSA-N
InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)

HIDE SMILES / InChI
Ioxilan is a nonionic X-ray contrast agent approved by the United States Food and Drug Administration for X-ray imaging contrast enhancement. Ioxilan can be administered intravenously for excretory urography and contrast-enhanced computed tomography (CT) imaging of the head and body. Ioxilan can also be given intraarterially for cerebral arteriograpy, coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography.

CNS Activity

Curator's Comment:: Iodinated contrast agents may cross the blood-brain barrier.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
OXILAN-300

Approved Use

INTRAARTERIAL: OXILAN® Injection (300 mgI/mL) is indicated for cerebral arteriography. OXILAN® Injection (350 mgI/mL) is indicated for coronary arteriography and left ventriculography, visceral angiography, aortography, and peripheral arteriography. INTRAVENOUS: OXILAN® Injection (300 mgI/mL) and OXILAN® Injection (350 mgI/mL) are indicated for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body.

Launch Date

8.1950402E11
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.1 min
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
23.5 min
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
100%
72.8 g single, intravascular
dose: 72.8 g
route of administration: Intravascular
experiment type: SINGLE
co-administered:
IOXILAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
Stabilization of the hydrophilic sphere of non-ionic monomers: are all protected in a similar way?
2001 Dec
Effects of nonionic contrast media on platelet aggregation: assessment by particle counting with laser-light scattering.
2001 Jan
Toward proteomics in uroscopy: urinary protein profiles after radiocontrast medium administration.
2001 May
[A state of delirium (confusion) following cerebral angiography with ioxilan: a case report].
2002 Jun
[Prospects of the use of non-ionic X-ray contrast media during endoscopic retrograde cholangiopancreatography].
2002 Nov-Dec
Reactions to radiocontrast media.
2002 Sep-Oct
Effects of hyperosmolar ionic and low osmolar non-ionic contrast media on coagulation times and some blood parameters in dogs: an in vivo study.
2003 Aug
Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography.
2003 Dec
Effects of hyperosmolar ionic and low osmolar non-ionic contrast media on acid base, blood gas and electrolyte status in dogs.
2004 Jun
Polyp size at CT colonography after electronic subtraction cleansing in an anthropomorphic colon phantom.
2005 Jul
Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials.
2005 Jul
Decrease in fluoroscopic cardiac silhouette excursion precedes hemodynamic compromise in intraprocedural tamponade.
2005 Nov
Quantitation of regional cerebral blood flow: the next chapter in digital subtraction angiography.
2006 Apr
Comparison of asymmetry in cerebral blood flow between brain hemispheres using digital subtraction angiography.
2006 Apr
Adrenocortical carcinoma: contrast washout characteristics on CT.
2006 Jul
Transient interruption of contrast on CT pulmonary angiography: proof of mechanism.
2007 May
A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity.
2007 Nov 14
Risk of thrombogenicity among nonionic radiocontrast agents.
2008 Jul
Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial.
2008 Sep 3
Ethyl 3-carb-oxy-5-nitro-benzoate.
2009 Apr 30
Contrast-induced nephropathy morbidity and mortality following percutaneous coronary intervention.
2009 Dec 15
Methyl 3-carboxy-5-nitrobenzoate.
2009 Jan 17
Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
2009 Jun 15
Contrast induced nephropathy in urology.
2009 Oct-Dec
Dimethyl 5-amino-2,4,6-triiodo-isophthalate.
2010 Jan 16
Patents

Patents

Sample Use Guides

300 mgI/mL or 350 mgI/mL injection
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
IOXILAN
INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
N-(2,3-DIHYDROXYPROPYL)-5-(N-(2,3-DIHYDROXYPROPYL)ACETAMIDO)-N'-(2-HYDROXYETHYL)-2,4,6-TRIIODOISOPHTHALAMIDE
Systematic Name English
IOXILAN [MI]
Common Name English
IOXILAN [JAN]
Common Name English
OXILAN
Brand Name English
IOXILAN [USP MONOGRAPH]
Common Name English
IOXILAN [USAN]
Common Name English
1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N-(2,3-DIHYDROXYPROPYL)-N'-(2-HYDROXYETHYL)-2,4,6-TRIIODO-
Systematic Name English
IOXILAN [INN]
Common Name English
IOXILAN [USP]
Common Name English
IOXILAN [VANDF]
Common Name English
NSC-760056
Code English
IOXILAN [MART.]
Common Name English
LOXILAN [VANDF]
Common Name English
IOXITOL
Common Name English
IOXILAN [USP-RS]
Common Name English
IOXILAN [ORANGE BOOK]
Common Name English
OXILAN-300
Brand Name English
1,3-BENZENEDICARBOXAMIDE, 5-(ACETYL(2,3-DIHYDROXYPROPYL)AMINO)-N1-(2,3-DIHYDROXYPROPYL)-N3-(2-HYDROXYETHYL)-2,4,6-TRIIODO-
Systematic Name English
Classification Tree Code System Code
WHO-VATC QV08AB12
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
NCI_THESAURUS C28500
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
NDF-RT N0000010258
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
NDF-RT N0000180185
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
WHO-ATC V08AB12
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
Code System Code Type Description
USP_CATALOG
1345206
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY USP-RS
PUBCHEM
3743
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
CAS
107793-72-6
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
DRUG BANK
DB09135
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
EVMPD
SUB08265MIG
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
NCI_THESAURUS
C65948
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
ChEMBL
CHEMBL1201075
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
MESH
C055357
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
FDA UNII
A4YJ7J11TG
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
MERCK INDEX
M6381
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY Merck Index
LACTMED
Ioxilan
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
INN
6301
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
WIKIPEDIA
Ioxilan
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
DRUG CENTRAL
1473
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
EPA CompTox
107793-72-6
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY
RXCUI
27793
Created by admin on Fri Jun 25 21:00:49 UTC 2021 , Edited by admin on Fri Jun 25 21:00:49 UTC 2021
PRIMARY RxNorm